Management of tumor lysis syndrome with standard continuous arteriovenous hemodialysis: case report and a review of the literature.
Tumor lysis syndrome (TLS) is a critical illness with few treatment options. This report describes the clinical course of a patient with non-Hodgkin's lymphoma, who developed TLS and required renal replacement therapy. Institution of the standard therapeutic approach, intermittent hemodialysis, was not possible because of persistent hypotension. Instead, the patient was treated with a short course of continuous arteriovenous hemofiltration (CAVH) and conventional continuous arteriovenous hemodialysis (CAVHD) with dialysate flow rate of 1 L/h), which resulted in effective control of serum uric acid, potassium, urea nitrogen, phosphorus, and extracellular fluid volume. This case is in distinction to a previous report of TLS treatment with CAVHD using 4 L/h dialysate flow rate. We conclude that continuous renal replacement therapies with standard dialysate flow rates and replacement volumes should be considered for the treatment of TLS, particulary if the syndrome is accompanied by hypotension.
Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
J R
JR
Schelling
F Z
FZ
Ghandour
T J
TJ
Strickland
J R
JR
Sedor
D058186:Acute Kidney Injury / Q000209:etiology / Q000628:therapy*; D005260:Female; D006440:Hemofiltration; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008875:Middle Aged; D006435:Renal Dialysis / Q000379:methods*; D015275:Tumor Lysis Syndrome / Q000209:etiology / Q000628:therapy*